Compare ATLC & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATLC | MLTX |
|---|---|---|
| Founded | 1996 | 2021 |
| Country | United States | Switzerland |
| Employees | 576 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | N/A | 2020 |
| Metric | ATLC | MLTX |
|---|---|---|
| Price | $106.60 | $18.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $90.00 | $27.50 |
| AVG Volume (30 Days) | 154.3K | ★ 1.1M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $477.21 | N/A |
| Revenue Next Year | $10.42 | N/A |
| P/E Ratio | $9.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $47.50 | $5.95 |
| 52 Week High | $112.61 | $62.75 |
| Indicator | ATLC | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.44 | 45.13 |
| Support Level | $91.14 | $15.54 |
| Resistance Level | $112.61 | $19.24 |
| Average True Range (ATR) | 4.99 | 0.98 |
| MACD | 0.44 | -0.15 |
| Stochastic Oscillator | 86.14 | 5.17 |
Atlanticus Holdings Corp is a financial technology company powering more inclusive financial solutions for Everyday Americans. It provides technology and other support services to lenders who offer an array of financial products and services to consumers. The company's products and services are reported through two reportable segments. Credit as a Service (CaaS) offers products including private label credit cards using the Fortiva and Curae brand names as well as merchant-associated brands and Auto Finance provides purchase and/or service loans secured by automobiles from or for, and also provides floor-plan financing for, a pre-qualified network of independent automotive dealers and automotive finance companies in the buy-here, pay-here used car business.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.